Last reviewed · How we verify

lactobacillus gasseri

Medical University of Vienna · FDA-approved active Small molecule ✓ Verified Jun 2026 Quality 2/100

lactobacillus gasseri is a Small molecule drug developed by Medical University of Vienna. It is currently FDA-approved.

Lactobacillus gasseri is a species of bacteria identified in 1980 by François Gasser and his associates. It has been studied as a probiotic in various clinical trials for conditions such as ulcerative colitis, vaginal flora, and irritable bowel syndrome.

At a glance

Generic namelactobacillus gasseri
SponsorMedical University of Vienna
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about lactobacillus gasseri

What is lactobacillus gasseri?

lactobacillus gasseri is a Small molecule drug developed by Medical University of Vienna.

Who makes lactobacillus gasseri?

lactobacillus gasseri is developed and marketed by Medical University of Vienna (see full Medical University of Vienna pipeline at /company/medical-university-of-vienna).

What development phase is lactobacillus gasseri in?

lactobacillus gasseri is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing